bs-12872R [Primary Antibody]
BLM/Blooms Syndrome Protein Blm Antibody
www.biossusa.com
[email protected]
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Rabbit

Target Protein: BLM/Blooms Syndrome Protein Blm

Immunogen Range: 1201-1417/1417


Clonality: Polyclonal

Isotype: IgG

Entrez Gene: 641

Source: KLH conjugated synthetic peptide derived from human BLM/Blooms Syndrome Protein Blm

Purification: Purified by Protein A.

Storage Buffer: 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Storage: Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Background:

Bloom?s syndrome is an autosomal recessive disorder characterized by pre- and post-natal growth deficiencies, sun sensitivity, immunodeficiency and a predisposition to various cancers. The gene responsible for Bloom?s syndrome, BLM, encodes a protein homologous to the RecQ helicase of E. coli and is mutated in most Bloom?s syndrome patients. One characteristic of Bloom?s syndrome is an increased frequency of sister chromatid exchange (SCE). BLM has been shown to unwind G4 DNA, and a failure of this function is thought to be responsible for the increased rate of SCE. BLM is known to be translocated to the nucleus, where its ATPase activity is stimulated by both single- and double-stranded DNA. Mutations in the yeast SGS1, a homolog of BLM, are known to cause mitotic hyperrecombination similiar to that observed in Bloom?s cells.

Size: 100ul

Concentration: 1ug/ul

Applications: WB(1:300-5000)
ELISA(1:500-1000)
IHC-P(1:200-400)
IHC-F(1:100-500)
IF(IHC-P)(1:50-200)
IF(IHC-F)(1:50-200)
IF(ICC)(1:50-200)
ICC(1:100-500)

Predicted Molecular Weight: 159


Predicted Cross Reactive Species: Human
Mouse
Rat
Dog
Cow
Sheep
Pig
Horse

For research use only. Not intended for diagnostic or therapeutic use.

PRODUCT SPECIFIC PUBLICATIONS
  • Xiao-Yan Ma. et al. Discovery of a Novel Bloom’s Syndrome Protein (BLM) Inhibitor Suppressing Growth and Metastasis of Prostate Cancer. INT J MOL SCI. 2022 Jan;23(23):14798Read more>>
  • Feng Cui. et al. ML216 Prevents DNA Damage-Induced Senescence by Modulating DBC1–BLM Interaction. CELLS-BASEL. 2023 Jan;12(1):145Read more>>
  • Guo, Yingchu. et al. BLM promotes malignancy in PCa by inducing KRAS expression and RhoA suppression via its interaction with HDGF and activation of MAPK/ERK pathway. J CELL COMMUN SIGNAL. 2022 Dec;:1-16Read more>>
  • Xiao-Yan Ma. et al. ML216-Induced BLM Helicase Inhibition Sensitizes PCa Cells to the DNA-Crosslinking Agent Cisplatin. MOLECULES. 2022 Jan;27(24):879Read more>>
  • Huang Mengqiu. et al. PARP1 negatively regulates transcription of BLM through its interaction with HSP90AB1 in prostate cancer. J TRANSL MED. 2023 Dec;21(1):1-19Read more>>